Infiltrating T-cell abundance combined with EMT-related gene expression as a prognostic factor of colon cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Soerjomataram I, Lortet-Tieulent J, Parkin DM, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet. 2012;380(9856):1840–1850.
   PubMed Web of Science ®Google Scholar
• Gallagher DJ, Kemeny N. Metastatic colorectal cancer: from improved survival to potential cure. Oncology. 2010;78(3–4):237–248.
   PubMed Web of Science ®Google Scholar
• Sharif S, O’Connell MJ, Yothers G, et al. FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer. Cancer Invest. 2008;26(9):956–963.
   PubMed Web of Science ®Google Scholar
• Bever KM, Le DT. An Expanding Role for Immunotherapy in Colorectal Cancer. J Natl Compr Canc Netw. 2017;15(3):401–410.
   PubMed Web of Science ®Google Scholar
• Adaptive Immune RA. Resistance: how cancer protects from immune attack. Cancer Discov. 2015;5(9):915–919.
   PubMed Web of Science ®Google Scholar
• Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–1086.
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–1964.
   PubMed Web of Science ®Google Scholar
• Galon J, Fridman WH, Pagès F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res. 2007;67(5):1883–1886.
   PubMed Web of Science ®Google Scholar
• Chen L, Gibbons DL, Goswami S, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014;5:5241.
   PubMed Web of Science ®Google Scholar
• Ye L-Y, Chen W, Bai X-L, et al. Hypoxia-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma induces an immunosuppressive tumor microenvironment to promote metastasis. Cancer Res. 2016;76(4):818–830.
   PubMed Web of Science ®Google Scholar
• Nieto MA, Huang RY, Jackson RA, et al. EMT: 2016. Cell. 2016;166(1):21–45.
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015 May;12(5):453–457.
   PubMed Web of Science ®Google Scholar
• Liberzon A, Birger C, Thorvaldsdóttir H, et al. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015 Dec 23;1(6):417–425.
   PubMed Web of Science ®Google Scholar
• Smith JJ, Deane NG, Wu F, et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology. 2010 Mar;138(3):958–968.
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.
   PubMed Web of Science ®Google Scholar
• Rooney MS, Shukla SA, Wu C J.,et.al. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160(1–2):48–61. J.,et.al
   PubMed Web of Science ®Google Scholar
• Gaujoux R, Seoighe C. CellMix: a comprehensive toolbox for gene expression deconvolution. Bioinformatics. 2013;29:2211–2212.
   PubMed Web of Science ®Google Scholar
• Wang L, Oh W, Zhu J. Disease-specific classification using deconvoluted whole blood gene expression. Sci Rep. 2016;6:32976.
   PubMed Web of Science ®Google Scholar
• Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.
   PubMed Web of Science ®Google Scholar
• Yoshihara K.ESTIMATE vignette. RDRR.io. 2013.
   Google Scholar
• Therneau TM, Grambsch PM. Modeling Survival Data: extending the Cox Model. New York: Springer; 2000. ISBN 0-387-98784-3.
   Google Scholar
• Uhlen M, Zhang C, Lee S, et al. A pathology atlas of the human cancer transcriptome. Science. 2017 Aug 18;357(6352):eaan2507. PMID: 28818916.
   PubMed Web of Science ®Google Scholar
• Ru B, Wong CN, Tong Y, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019 Oct 15;35(20):4200–4202.
   PubMed Web of Science ®Google Scholar
• Frydrychowicz M, Boruczkowski M, Kolecka-Bednarczyk A, et al. The dual role of treg in cancer. Scand J Immunol. 2017;86(6):436–443.
   PubMed Web of Science ®Google Scholar
• Kishton RJ, Sukumar M, Restifo NP. Metabolic regulation of T cell longevity and function in tumor immunotherapy. Cell Metab. 2017;26(1):94–109.
   PubMed Web of Science ®Google Scholar
• Huang SH, Li Y, Zhang J, et al. Epidermal growth factor receptor-containing exosomes induce tumor-specific regulatory T-cells. Cancer Invest. 2013;31(5):330–335.
   PubMed Web of Science ®Google Scholar
• Engels CC, Charehbili A, van de Velde CJ, et al. The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis. Breast Cancer Res Treat. 2015;149(3):587–596.
   PubMed Web of Science ®Google Scholar
• Kumagai S, Togashi Y, Kamada T, et al. The PD-1 expression balance between effector and regulatory T-cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol. 2020;21(11):1346–1358.
   PubMed Web of Science ®Google Scholar
• Wei Y, Guixiang L. Research progress of PD-1/PD-L 1 inhibitors for colorectal cancer. Chinese J Clin Oncol. 2018;45(3):157–160.
   Google Scholar
• Seiler R, Ashab HAD, Erho N, et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol. 2017;72(4):544–554.
   PubMed Web of Science ®Google Scholar
• Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009;69(10):4116–4124.
   PubMed Web of Science ®Google Scholar
• Mak MP, Tong P, Diao L, et al. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clin Cancer Res. 2016;22(3):609–620.
   PubMed Web of Science ®Google Scholar
• Hugo W, Zaretsky JM, Sun L, et al. Genomic and transcriptomic features of response to Anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165(1):35–44.
   PubMed Web of Science ®Google Scholar
• Suarez-Carmona M, Lesage J, Cataldo D, et al. EMT and inflammation: inseparable actors of cancer progression.Mol Oncol. 2017;11(7):805–823.
   PubMed Web of Science ®Google Scholar
• Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14(6):818–829.
   PubMed Web of Science ®Google Scholar
• Jolly MK, Boareto M, Huang B, et al. Implications of the hybrid epithelial/mesenchymal phenotype in metastasis. Front Oncol. 2015;5:155.
   PubMed Web of Science ®Google Scholar
• Barrallo-Gimeno A, Nieto MA. The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development. 2005;132(14):3151–3161. PMID: 15983400
   PubMed Web of Science ®Google Scholar
• Brabletz T, Kalluri R, Nieto MA, et al. EMT in cancer. Nat Rev Cancer. 2018;18(2):128–134.
   PubMed Web of Science ®Google Scholar
• Terry S, Buart S, Tan TZ, et al. Acquisition of tumor cell phenotypic diversity along the EMT spectrum under hypoxic pressure: consequences on susceptibility to cell-mediated cytotoxicity. Oncoimmunology. 2017;6(2):e1271858.
   PubMed Web of Science ®Google Scholar
• Noman MZ, Janji B, Abdou A, et al. The immune checkpoint ligand PD-L1 is up-regulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200. Oncoimmunology. 2017;6(1):e1263412.
   PubMed Web of Science ®Google Scholar
• Dongre A, Rashidian M, Reinhardt F, et al. Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas. Cancer Res. 2017;77(15):3982–3989.
   PubMed Web of Science ®Google Scholar
• Akalay I, Janji B, Hasmim M, et al. Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Res. 2013;73(8):2418–2427.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhan H, Zhan H. Communication between EMT and PD-L1 signaling: new insights into tumor immune evasion. Cancer Lett. 2020;468:72–81.
   PubMed Web of Science ®Google Scholar
• Korpal M, Lee ES, Hu G, et al. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem. 2008;283(22):14910–14914.
   PubMed Web of Science ®Google Scholar
• Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004;117(7):927–939.
   PubMed Web of Science ®Google Scholar
• Chakrabarti R, Hwang J, Andres Blanco M, et al. Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nat Cell Biol. 2012;14(11):1212–1222.
   PubMed Web of Science ®Google Scholar
• Liu Y, El-Naggar S, DS D, et al. Zeb1 links epithelial-mesenchymal transition and cellular senescence. Development. 2008;135(3):579–588.
   PubMed Web of Science ®Google Scholar
• Salazar Y, Zheng X, Brunn D, et al. Microenvironmental Th9 and Th17 lymphocytes induce metastatic spreading in lung cancer. J Clin Invest. 2020;130(7):3560–3575.
   PubMed Web of Science ®Google Scholar
• Jordan NV, Johnson GL, Abell AN. Tracking the intermediate stages of epithelial-mesenchymal transition in epithelial stem cells and cancer. Cell Cycle. 2011;10(17):2865–2873.
   PubMed Web of Science ®Google Scholar
• Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331(6024):1559–1564.
   PubMed Web of Science ®Google Scholar
• Tan TZ, Miow QH, Miki Y, et al. Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Mol. 2014;6(10):1279–1293.
   PubMed Web of Science ®Google Scholar
• Hu L, Fang L, Zhang ZP, et al. TPM1 is a novel predictive biomarker for gastric cancer diagnosis and prognosis. Clin Lab. 2020;66:4.
   Web of Science ®Google Scholar
• Kunitomi H, Kobayashi Y, Wu RC, et al. LAMC1 is a prognostic factor and a potential therapeutic target in endometrial cancer. J Gynecol Oncol. 2020;31(2):e11.
   PubMed Web of Science ®Google Scholar
• Yue H, Li W, Chen R, et al. Stromal POSTN induced by TGF-β1 facilitates the migration and invasion of ovarian cancer. Gynecol Oncol. 2021;160(2):530–538.
   PubMed Web of Science ®Google Scholar
• Chen L, Lu D, Sun K, et al. Identification of biomarkers associated with diagnosis and prognosis of colorectal cancer patients based on integrated bioinformatics analysis. Gene. 2019;692:119–125.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Ghosh A, VonHoff DD, et al. Cyr61/CCN1 targets for chemosensitization in pancreatic cancer. Oncotarget. 2019;10(38):3579–3580.
   PubMedGoogle Scholar
• Huang C, Wang M, Wang J, et al. Suppression MGP inhibits tumor proliferation and reverses oxaliplatin resistance in colorectal cancer. Biochem Pharmacol. 2020;22:114390.
   PubMed Web of Science ®Google Scholar
• Oya H, Kanda M, Sugimoto H, et al. Dihydropyrimidinase-like 3 is a putative hepatocellular carcinoma tumor suppressor. J Gastroenterol. 2015;50(5):590–600.
   PubMed Web of Science ®Google Scholar
• Ge T, Xiang P, Mao H, et al. Inhibition of miR-96 enhances the sensitivity of colorectal cancer cells to oxaliplatin by targeting TPM1. Exp Ther Med. 2020 Sep;20(3):2134–2140.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Cantor H. CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol Res. 2014 2;Feb(2):91–98.
   Google Scholar
• Konkel JE, Zhang D, Zanvit P, et al. Transforming growth factor-β signaling in regulatory T cells controls T helper-17 cells and tissue-specific immune responses. Immunity. 2017 Apr 18;46(4):660–674.
   PubMed Web of Science ®Google Scholar
• Schreiber TH, Wolf D, Tsai MS, et al. Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation. J Clin Invest. 2010 Oct;120(10):3629–3640.
   PubMed Web of Science ®Google Scholar